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ABSTRACT
Objective: Aims of this study were to determine the IgG and IgM seropositivity to parvovirus B19
during the three trimesters of pregnancy.
Methods: Initially, a total of 1,047 pregnant women were included in a prospective study. Blood
samples were obtained from 343, 406 and 298 cases in the first, second and third trimesters,
respectively. To study the incidence of seroconversion, a second sample of blood was obtained 2-4
weeks later from the first 100 cases, who were IgG and IgM negative in the first trimester.
Results: The seroprevalence of parvovirus B19 IgG and IgM was 53.3% and 2.2%, respectively.
The incidence of seroconversion was 16.5%. The rate of fetal loss was 15.4% in patients with acute
infection, all of which occurred in the first two trimesters.
Conclusions: The percentage of IgG positive cases is significantly higher in first and second
trimesters compared to the third trimester. The seroconversion rate was 16.5%. Infect. Dis. Obstet.
Gynecol. 7:287-292, 1999. (C) 1999Wiley-Liss, Inc.
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ossart et al. discovered the parvovirus B 19 ac-
cidentally in 1975 while they were evaluating
screening tests for the hepatitis B virus. Parvovi-
ruses are small, round viruses with a single-
stranded DNA genome that lacks a lipid envelope.
Infection with parvovirus B19 is usually spread by
the respiratory route, but may be transmitted by
blood components or blood products, z Parvovirus
B19 has been implicated as a primary etiologic
agent of erythema infectiosum (fifth disease) and
aplastic crisis in patients with chronic hemolytic
anemias.3,4,s It has also been associated with arthri-
tis.6,7
Human parvovirus B19 is now a recognized
cause of non-immune hydrops fetalis and intrauter-
ine fetal death.8,9,1,11 However, maternal parvovi-
rus B 19 infection is usually followed by a successful
outcome with delivery of a normal infant. Since
parvovirus B19 has a propensity for infecting rap-
idly dividing cells, particularly erythroblasts, the
greatest risk to the fetus occurs during the first 20
weeks of pregnancy, and especially between weeks
10 and 20 which coincides with the major develop-
ment of erythroid precursors, lz,13
This study is aimed at studying the pattern of
parvovirus B19 infection during different trimes-
ters of pregnancy and the incidence of seroconver-
sion in the obstetric population of Kuwait.
SUBJECTS AND METHODS
Initially, a total of 1,047 pregnant women were in-
cluded in a prospective study which was conducted
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Fig. I. An outline of patients included in the follow-up
study.
in a primary health care center. Blood samples were
obtained from 343, 406 and 298 cases in the first,
second and third trimesters, respectively. To study
the incidence of seroconversion, a second sample
of blood was obtained 2--4 weeks later from the first
100 cases, who were IgG and IgM negative in the
first trimester (Figure 1).
Acute infection was defined by the presence of
IgM antibodies to parvovirus B 19 at the first deter-
mination or by the development of IgG or/and IgM
antibodies to parvovirus in previously seronegative
women.
The symptoms checked for were fever, rash and
arthritis alone or in combination.
Laboratory Methods
Human serum IgG and IgM antibodies to parvovi-
rus B19 were detected by a high quality enzyme
immunoassay (IDEIA, DAKO) which are devel-
oped to provide the optimal specificity and sensi-
tivity of the assay system. This is obtained by: (1)
use of non-infectious, empty viral capsid as anti-
gen, produced in insect cells infected with recom-
binant baculovirus encoding for the capsid protein
VP2, (2) use of u-capture technique for the detec-
tion of B 19 specific IgM antibodies. The sensitivity
and specificity of anti-B19 IgG assay are based on
that of the golden standard, radioimmunoassay.
The sensitivity of the assay is. 98% while the speci-
ficity is 96%. 14
Statistical Methods
The statistical method used was the Z-test of pro-
portion and the chi-square test for association be-
tween categorical variables. The value ofP -< 0.05
was used as the cut-off level of significance.
RESULTS
The demographic features of the 1,047 patients in-
cluded in the study are shown in Table 1. The
mean maternal age and parity of the patients who
were in the third trimester were significantly
higher compared to patients who were in the first
and second trimester (P < 0.01, P < 0.0001, respec-
tively).
The overall prevalence for parvovirus B19 IgG
positivity was 53.3% and IgM seropositivity was
2.2% at the initial testing. The result of parvovirus
B19 IgG and IgM seropositivity is shown in Table
2. The prevalence of parvovirus B19 IgM seropos-
itivity in the three trimesters did not show signifi-
cant difference. However, IgG seropositivity was
significantly higher in the first and second trimes-
ter (54.5 and 59.5%, respectively) compared to
third trimester (47.6%) (P < 0.01, P < 0.001, respec-
tively).
Parity and Parvovirus B I9 IgG and IgM
Seropositivity in Different Trimesters
The percentage of IgM positive cases with a parity
of 5 or more is significantly higher in all three tri-
mesters compared to mothers in the lower parity
groups (Figure 2). IgG seroprevalence in the third
trimester is significantly lower than first and second
trimester in all parity groups (except parity of 5 or
more) (Figure 3).
Age and Parvovirus B 9 IgG and IgM
Seropositivity in Different Trimesters
There was no statistically significant difference
among the different age groups in terms of IgM
seropositivity in different trimesters (Figure 4).
Overall prevalence of IgG seropositivity was sig-
nificantly affected by maternal age with the highest
seropositivity in mothers with age groups -< 24 and
25-35 compared to mothers in age group of-> 36
irrespective of the trimesters. When we studied it
in relation to trimester of pregnancy, the preva-
lence of IgG antibodies to parvovirus B19 in the
age groups < 24 and 25-35 was still higher in first
and second trimesters compared to third trimester
(P < 0.01) (Figure 5).
Nationality and Parvovirus B I9 IgG and IgM
SeropositiviW in Different Trimesters
IgG seropositivity was significantly higher in non-
Kuwaiti mothers (58.5%) when compared to Ku-
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TABLE I. Distribution of maternal demographic features in the three trimesters
st trimester 2nd trimester 3rd trimester
Maternal feature (343) (406) (298) ’P’ value
Total
(1047)
Age (mean + SD) 26.92 + 5.99 27.28 + 5.06 28.38 + 5.97 <0.01"
Parity (mean +/- SD) 1.25 +/- 1.71 1.22 +/- 1.5 2.13 +/- 1.95 <0.0001"
Nationality [N (%)]
Kuwaiti 106 (29.2) 66 (18.2) 191 (52.6) <0.0001 #
Non-Kuwaiti 237 (39.9) 340 (49.7) 107 (I 5.6)
27.53 +/- 5.66
1.55 +/- 1.79
363
684
*P value by one-way ANOVA.
#P value by chi-square.
TABLE 2. Parvo B I9 IgM and IgG seropositivity in the three trimesters
IgM
Trimester (-ve) (+ve)* (E)
IgG
(-ve) (+ve)
# (E)
st 321 (93.6) 10 (2.9) 12 (3.5)
2nd 383 (94.3) 6 (I.5) 17 (4.2)
3rd 285 (95.6) 7 (2.3) 6 (2)
152 (44.3) 188 (54.8) 3 (0.9)
153 (37.7) 243 (59.8) 10 (2.5)
166 (55.7) 127 (42.6) 5 (I .7)
)% *P value (P NS) by chi-square.
#P value (P < .0001) by chi-square.
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Fig. 2. Parvovirus B I9 IgM seropositivity in relation to
maternal parity and different trimesters.
waiti mothers (43.5%) (P < 0.0001). The distribu-
tion of IgG seropositive mothers in the three tri-
mesters is shown in Figure 6. IgG seropositivity is
significantly higher in Kuwaiti mothers in the third
trimester (P < 0.0001) (Figure 6). IgM seropositiv-
ity was higher among Kuwaiti mothers (3.6%) com-
pared to non-Kuwaiti mothers (1.5%) (P < 0.05).
Distribution of IgM seropositive mothers in rela-
tion to nationality and trimesters is shown in Fig-
ure 7.
Logistic regression of IgG seropositivity as de-
pendent variable and age, parity and trimester of
pregnancy as independent variables selected the
trimester of pregnancy as the only significant factor
(P < 0.05). The same was done for IgM seroposi-
tivity and none of the factors were significantly
related to the IgM seropositivity.
80,
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Fig. 3. Parvovirus B I9 IgM seropositivity in relation to
maternal parity and different trimesters.
Acute Infection
Twenty three patients were parvovirus B19 IgM
positive in the initial testing with their pregnancy
outcome. Ten of these were in the first trimester,
six in the second and seven in the third trimester.
Four of the abortions occurred between 8-12
weeks and one of at 16 weeks of gestational age.
Therefore, the abortion rate among the parvovirus
B19 IgM positive group in the first and second
trimester was 31.25%.
Among the 100 patients who were retested 2-4
weeks after an initial IgG and IgM negative result,
97 completed the two tests. Figure shows the
pregnancy outcome of these patients. The rate of
parvovirus B19 acute infection between 9-14
weeks is 16.5%. The abortion rate in the first tri-
mester in patients with acute infection was 19.2%
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Fig. 4. Parvovirus B I9 IgM seropositivity in relation to
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Fig. 6. Parvovirus B I9 IgM seropositivity in relation to na-
tionality of the mother and different trimesters.
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Fig. 5. Parvovirus B I9 IgM seropositivity in relation to
maternal parity and different trimesters.
compared to 3.7% who were seronegative between
9-14 weeks, and the difference is statistically sig-
nificant (P < 0.01). Of the 32 who had acute infec-
tion in the first or second trimester, the abortion
rate was 18.75%. In mothers with acute infection,
the abortion rate was 14.3% in Kuwaiti and 16.7%
in non-Kuwaiti mothers.
Symptom of Acute Infection
Only 17.9% mothers with acute infection were
symptomatic and none of these mothers had fetal
loss. Six of these symptomatic cases were in the
first trimester. There was no significant difference
in abortion rate among symptomatic IgM positive
(0/6) and asympytomatic IgM positive mothers (5/
ZO).
DISCUSSION
In most of the mothers with confirmed parvovirus
B 19 infection, the pregnancy outcome is favorable,
whereas in others for reasons not well understood,
adverse fetal outcome like miscarriages, hydrops
fetalis and death may occur.
The fetus seems to be most susceptible to par-
Kuwaiti
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[] 3rd trimester
Non-Kuwaiti
Fig. 7. Parvovirus B I9 IgM seropositivity in relation to na-
tionality of the mother and different trimesters.
vovirus B19 infection during the first and second
trimester of pregnancy and especially between
weeks 10 and 2011 which coincide with the major
development of the erythroid precursors. Parvovi-
rus B19 has a propensity for infecting rapidly di-
viding cells, particularly erythroblasts. Between the
third and sixth months of pregnancy the fetal red
blood cell mass increases thirty times, with a risk of
developing anemia if the fetus is infected by par-
vovirus virus B19 is. By the third trimester, the fe-
tus is able to mount a more effective immune re-
sponse to the virus, which may account for the de-
crease in fetal loss at this stage of the pregnancy.
In a large prospective study, 186 women sero-
converted during pregnancy. There were a total of
30 pregnancy losses, 7 ofwhich occurred in the first
12 weeks of gestation, 20 during weeks 13-20,
between 21-27 weeks, between 28-40 and one at
an unknown time. 11 In another study, 134 IgM
positive pregnant women were included. Of these,
46 were in the first 8 weeks of pregnancy. Fifteen
percent of these resulted in pregnancy loss, 66
cases were between 10-18 weeks, out of which
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there were 11 (17%) fetal deaths. Of the 13 women
between 19-27 weeks, none had a fetal loss.1 We
found in the initial testing that there were a total of
5 fetal losses among the 23 IgM positive cases, 4 of
which occurred 8-12 weeks of gestation and oc-
curred at 16 week of gestation. In the subsequent
testing for seroconversion, there was one case of
fetal loss which occurred at 12 weeks of gestation.
Incidence of fetal loss secondary to parvovirus
B19 was initially estimated to be as high as 26-
38%. 16-17 However, recently this loss is thought to
be much lower, usually < 10%. 11,18,19 In our study
group, the abortion rate in those patients who had
acute infection was 15.4%. Although we detected
antibodies to parvovirus B19 in women who
aborted, we cannot state that parvovirus B19 was
the cause, since we did not perform PCR for par-
vovirus B 19 DNA and electron microscopy for viral
particles. Therefore incidence of fetal loss second-
ary to Parvovirus B19 may be lower than we re-
ported.
The incidence of acute infection during preg-
nancy is reported to be 1.5-3.7%. 18,z Our serocon-
version rate of 16.5% is much higher, which may be
related to a number of epidemiological variables
including climate.
The reported incidence of asymptomatic infec-
tion after parvovirus B 19 infection is in the range of
20-53% in non-pregnant patients.21,22 However,
the incidence of asymptomatic infection in preg-
nant patients was shown to be higher reaching
70%. 18 Accordingly, the estimate of the incidence
of parvovirus B19 infection in pregnancy on the
basis of clinical symptoms may underestimate the
true incidence of acute infection during pregnancy.
In our group, the incidence of symptoms in acute
infection group is even lower (17.9%). Previously it
has been shown that pregnant women with asymp-
tomatic parvovirus B19 infection are at a greater
risk than those reporting symptoms.
13 Similarly in
our study, of the patients with acute infection in
the first trimester, 20% mothers with asymptomatic
infection aborted, while none (0/6) of the mothers
with symptoms aborted. However, the difference
was not statistically significant.
Seroprevalence of IgG antibodies to parvovirus
B19 increases with age. A survey in the USA
showed a gradual increase in seropositivity with age
ranging from as low as 19% in children under 10
years of age to 67% in individuals over 49 years of
age, suggesting continuing exposure to the virus,z
A Japanese study showed that the prevalence of
human parvovirus B19 rose with increasing age,
starting just above 10% in children under 10 years
and reached more than 50% in subjects over 60
years,z3 Contrary to other reports our study showed
the highest IgG parvovirus B19 seroprevalence
among patients who were less than 36 years of age.
The percentage of IgM seropositivity in grandmul-
tiparas was higher compared to mothers with lower
parity. It seems that nationality was a major factor
affecting the prevalence of IgG antibodies and
IgM. This might reflect the general effect of epi-
demiology of parvovirus B19 in the countries from
which non-Kuwaiti population, in Kuwait, came
from. The lower prevalence of IgG seropositivity
among Kuwaiti put them at a higher risk of acquir-
ing parvovirus B 19 during pregnancy, especially in
countries with large numbers of visitors and an epi-
demic could follow.
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